Manchester Capital Management LLC Has $71,000 Stake in IDEXX Laboratories, Inc. $IDXX

Manchester Capital Management LLC reduced its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 45.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 132 shares of the company’s stock after selling 110 shares during the period. Manchester Capital Management LLC’s holdings in IDEXX Laboratories were worth $71,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in IDXX. Bank of New York Mellon Corp boosted its position in shares of IDEXX Laboratories by 156.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,451,390 shares of the company’s stock valued at $778,439,000 after purchasing an additional 884,808 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in IDEXX Laboratories by 71.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,988,912 shares of the company’s stock worth $835,244,000 after purchasing an additional 825,965 shares in the last quarter. Generation Investment Management LLP acquired a new position in IDEXX Laboratories in the second quarter valued at approximately $304,277,000. Select Equity Group L.P. acquired a new stake in shares of IDEXX Laboratories during the 1st quarter worth approximately $194,834,000. Finally, Nuveen LLC bought a new stake in shares of IDEXX Laboratories in the 1st quarter valued at $179,784,000. 87.84% of the stock is owned by institutional investors.

IDEXX Laboratories Trading Down 1.4%

NASDAQ:IDXX opened at $755.96 on Thursday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.11 and a quick ratio of 0.79. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $769.98. The company has a market cap of $60.36 billion, a PE ratio of 62.94, a PEG ratio of 4.06 and a beta of 1.62. The firm has a 50-day moving average of $663.01 and a 200-day moving average of $602.29.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Monday, November 3rd. The company reported $3.22 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.14 by $0.08. The business had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.07 billion. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The company’s quarterly revenue was up 13.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.80 EPS. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. As a group, equities research analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently issued reports on IDXX. Jefferies Financial Group reissued a “buy” rating and set a $830.00 target price on shares of IDEXX Laboratories in a research note on Tuesday, November 4th. Weiss Ratings reiterated a “hold (c+)” rating on shares of IDEXX Laboratories in a report on Tuesday. Morgan Stanley increased their price objective on shares of IDEXX Laboratories from $765.00 to $805.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 4th. UBS Group boosted their target price on IDEXX Laboratories from $710.00 to $750.00 and gave the company a “neutral” rating in a research report on Tuesday, November 4th. Finally, BTIG Research increased their price target on IDEXX Laboratories from $785.00 to $830.00 and gave the stock a “buy” rating in a report on Tuesday, November 4th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $730.50.

Insider Activity

In related news, EVP Nimrata Hunt sold 9,425 shares of the company’s stock in a transaction on Friday, November 7th. The stock was sold at an average price of $703.34, for a total transaction of $6,628,979.50. Following the completion of the sale, the executive vice president owned 21,149 shares in the company, valued at approximately $14,874,937.66. This represents a 30.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 0.98% of the stock is currently owned by insiders.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.